



Press release from Emotra AB (publ)

Göteborg, May 7, 2018

Emotra: Agreement with research group on compensation for clinical tests

Emotra AB (“Emotra”) hereby announces that an agreement has been reached with a group of researchers at the faculty of medicine at the University of Warsaw. The agreement concerns financial compensation for EDOR® tests in a clinical study. The study in question is a continuation of a research project that was started in connection with the European EUDOR-A multi-centre study and will be conducted during 2018.

Research on EDOR® and hyporeactivity is strategically important for Emotra. The Company will continue to encourage and support clinics that show an interest in and have the capacity to conduct relevant research studies. For one study, which is in fact a continuation of work that was started in connection with EUDOR-A, Emotra and the research group have agreed on compensation amounting to 1,840 EUR for a total of 40 tests. This agreement provides the researchers with predictability concerning the cost of the study, while at the same time allowing Emotra to support them by offering an attractive pricing.

Comments from Emotra’s R&D Manager Lars-Håkan Thorell:

- *We are very pleased to see the marked interest in EDOR® and the commitment to continued studies. From our side, we hope to be able to support and participate in the scientific work, but also in the process of furthering our knowledge about hyporeactivity. It is very satisfying to see new and younger talents with the ambition to continue developing this subject area.*

Daniel Poté, Emotra’s Marketing Manager, says:

- *From a market perspective, studies like this are strategically important, not least for the establishment of an initial platform with customers who work actively with EDOR®. The introduction of EDOR® in clinical practice raises both specific and general questions that these studies can answer. Studies also increase interest in the method and provide a basis for relevant discussions with the different clinic representatives.*

Emotra will continue to actively support research initiatives concerning EDOR® in order to further develop our knowledge about hyporeactivity and the use of the method.

For further information about the Company, please contact:

Claes Holmberg, CEO, telephone: +46 708 25 45 47, E-mail: claes@emotra.se

Emotra AB (publ) is a medical technology company that carries out research, development, clinical studies and marketing in the area of suicide prevention. The Company’s method, EDOR®, is a proprietary, objective and quantitative diagnostic, psychophysiological test for detecting hyporeactivity in patients suffering from depression. During the test, the patient listens to a series of audio signals. The patient’s response, in the form of very small changes in dermal electric conductivity, is measured and analysed. This extremely sensitive and specific test of suicidal risk has been developed as the result of research.

Emotra AB (publ), Göteborgsvägen 88, SE-433 63 Sävedalen, Sweden
Tel: +46 708 25 45 47, www.emotra.se